Eupraxia Pharmaceuticals
VICTORIA, A1 · Biotechnology · 35 employees
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia's product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In a
Funding history
- Series seed — $1.9M — Nov 2024
- Series pre-seed — $128K — Aug 2023
- Series pre-seed — $38K — Apr 2016
Recent signals
- May 01, 2026: Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer
- Feb 18, 2025: Eupraxia Pharmaceuticals Appoints Alex Rothwell as Chief Financial Officer
- Nov 08, 2024: Raised $1.9M in Series seed
- Aug 22, 2023: Raised $128K in Series pre-seed
- Apr 18, 2016: Raised $38K in Series pre-seed
See plans & pricing → Track Eupraxia Pharmaceuticals’s funding, hiring, and signals — with verified contacts — on Fundz.